Pipamperone/Risperidone

匹泮哌隆/利培酮

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePipamperone/Risperidone
Drug Alias NamePipamperone+Risperidone利培酮+匹泮哌隆Risperidone+Pipamperone利培酮/匹泮哌隆匹泮哌隆+利培酮 +[7] 
ClassificationSmall molecules
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D4 receptor antagonistsDopamine D2 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptorDopamine D4 receptor
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsYes RisperidonePipamperone Hydrochloride
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPharmaneuroboost Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharmaneuroboost Nv
Active IndicationsN/A
Inactive IndicationsSchizophrenia

Other Information

ATC CodeN/A
Related LinksN/A